In addition to CCL2, CCL22, and IL-10, TAM-associated markers CCL5 and SPP1 (secreted phosphosprotein 1, also known as osteopontin, OPN) are promising targets for novel cancer immunotherapy [34,35]. This evidence concerns the gene IL10 and cancer.